Details of the Drug Reposition

General Information of This Drug (ID: DMQNWRD)

Drug Name
Oxaliplatin   DMQNWRD
Synonyms Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
13 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Rectum mucinous adenocarcinoma DIS75WFS N.A. Approved [1]
Rectal neoplasm DISB4UZ0 N.A. Approved [1]
Peritoneal neoplasm DIS2ZMIF N.A. Approved [1]
Metastasis from malignant tumor of colon DIS175N9 N.A. Approved [1]
Gallbladder carcinoma DISD6ACL N.A. Approved [1]
Endocrine gland neoplasm DISGQU9D N.A. Approved [1]
Colorectal carcinoma DIS5PYL0 N.A. Approved [1]
Colon adenocarcinoma DISDRE0J N.A. Approved [1]
Appendiceal neoplasm DIS2XZ0U N.A. Approved [1]
Nasopharyngeal carcinoma DISAOTQ0 2B6B Approved [1]
Rectal adenocarcinoma DIS8R9VO 2B92 Approved [1]
Cholangiocarcinoma DIS71F6X 2C12.10 Approved [1]
Adenocarcinoma DIS3IHTY 2D40 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Indications(s)
3 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Rectal signet ring cell adenocarcinoma DISORL5H N.A. Discontinued in Phase 2 [2]
Colonic neoplasm DISSZ04P N.A. Discontinued in Phase 2 [3]
Colorectal cancer DISNH7P9 2B91.Z Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Colorectal neoplasm DISR1UCN N.A. Discontinued in Phase 1 [5]
------------------------------------------------------------------------------------
2 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric cancer DISXGOUK 2B72 Investigative [1]
Colon cancer DISVC52G 2B90.Z Investigative [1]
------------------------------------------------------------------------------------

References

1 Oxaliplatin FDA Label
2 ClinicalTrials.gov (NCT01312935) Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI). U.S. National Institutes of Health.
3 Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
4 High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study
5 Effects of Propranolol on Responses to Drug-Related Imagery Scripts